Aerovate Therap 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
4 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
imatinib dry powder (AV-101) / Aerovate Therap
2021-006864-25: Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial – Follow Up Long Term Extension (IMPAHCT-FUL) Ensayo clínico de Imatinib inhalado para la hipertensión arterial pulmonar - Extensión de seguimiento a largo plazo (IMPAHCT-FUL)

Ongoing
3
462
Europe
AV-101, Inhalation powder, hard capsule
Aerovate Therapeutics, Inc., Aerovate Therapeutics Inc
Pulmonary Arterial Hypertension (PAH) Hipertensión arterial pulmonar (HAP), PAH includes rare, chronic cardiopulmonary diseases involving common pathologic features of inappropriate cell growth resulting in increasedresistance to blood flow through the pulmonary vasculature. La HAP incluye patologías cardiopulmonares raras y crónicas que implican patologías de crecimiento celular inadecuado, provoca mayor resistencia al flujo sanguíneo a través de la vasculatura pulmonar., Diseases [C] - Cardiovascular Diseases [C14]
 
 
IMPAHCT-FUL, NCT05557942 / 2021-006864-25: Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension

Terminated
3
186
Europe, Canada, US, RoW
AV-101
Aerovate Therapeutics, Aerovate Therapeutics Inc
Pulmonary Arterial Hypertension
08/24
08/24
2021-001910-13: Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) or A Phase 2b/3, Randomized, Controlled, 24-week Dose Ranging and Confirmatory Study of AV-101 in Patients with PAH.

Not yet recruiting
2/3
462
Europe
AV-101, [AV-101], Capsule
Aerovate Therapeutics, Inc., Aerovate Therapeutics, Inc.
Pulmonary Arterial Hypertension (PAH), PAH includes rare, chronic cardiopulmonary diseases involving common pathologic features of inappropriate cell growth resulting in increased resistance to blood flow through the pulmonary vasculature., Diseases [C] - Cardiovascular Diseases [C14]
 
 
IMPAHCT, NCT05036135 / 2021-001910-13: A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)

Terminated
2/3
202
Europe, Canada, US, RoW
AV-101, Placebo
Aerovate Therapeutics, Aerovate Therapeutics, Inc.
Pulmonary Arterial Hypertension
08/24
08/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
imatinib dry powder (AV-101) / Aerovate Therap
2021-006864-25: Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial – Follow Up Long Term Extension (IMPAHCT-FUL) Ensayo clínico de Imatinib inhalado para la hipertensión arterial pulmonar - Extensión de seguimiento a largo plazo (IMPAHCT-FUL)

Ongoing
3
462
Europe
AV-101, Inhalation powder, hard capsule
Aerovate Therapeutics, Inc., Aerovate Therapeutics Inc
Pulmonary Arterial Hypertension (PAH) Hipertensión arterial pulmonar (HAP), PAH includes rare, chronic cardiopulmonary diseases involving common pathologic features of inappropriate cell growth resulting in increasedresistance to blood flow through the pulmonary vasculature. La HAP incluye patologías cardiopulmonares raras y crónicas que implican patologías de crecimiento celular inadecuado, provoca mayor resistencia al flujo sanguíneo a través de la vasculatura pulmonar., Diseases [C] - Cardiovascular Diseases [C14]
 
 
IMPAHCT-FUL, NCT05557942 / 2021-006864-25: Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension

Terminated
3
186
Europe, Canada, US, RoW
AV-101
Aerovate Therapeutics, Aerovate Therapeutics Inc
Pulmonary Arterial Hypertension
08/24
08/24
2021-001910-13: Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) or A Phase 2b/3, Randomized, Controlled, 24-week Dose Ranging and Confirmatory Study of AV-101 in Patients with PAH.

Not yet recruiting
2/3
462
Europe
AV-101, [AV-101], Capsule
Aerovate Therapeutics, Inc., Aerovate Therapeutics, Inc.
Pulmonary Arterial Hypertension (PAH), PAH includes rare, chronic cardiopulmonary diseases involving common pathologic features of inappropriate cell growth resulting in increased resistance to blood flow through the pulmonary vasculature., Diseases [C] - Cardiovascular Diseases [C14]
 
 
IMPAHCT, NCT05036135 / 2021-001910-13: A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)

Terminated
2/3
202
Europe, Canada, US, RoW
AV-101, Placebo
Aerovate Therapeutics, Aerovate Therapeutics, Inc.
Pulmonary Arterial Hypertension
08/24
08/24

Download Options